Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy

Executive Summary

Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.

You may also be interested in...

Sanofi’s Tzield Delays Children’s Type 1 Diabetes Progression, But Falls Short On Clinical Impact

Sanofi paid $2.9bn for Tzield and its developer Provention earlier this year, but a mixed readout in its key Phase III study will raise doubts among analysts about its long-term prospects in later-stage patients.

Sana Curbs Cell Therapy Ambitions Again, Including Retreat From In Vivo CAR-T

Launched with an ambitious R&D vision for cell therapies two years ago, Sana is now having to narrow its focus while it awaits the first of its Phase I readouts.

Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma

Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts